[1]谢慰,刘慧婷,刘彬彬,等.基于“木曰敷和”理论探讨原发性肝癌的论治[J].陕西中医,2025,46(10):1386-1390.[doi:DOI:10.3969/j.issn.1000-7369.2025.10.017]
　XIE Wei,LIU Huiting,LIU Binbin,et al.Exploration of the treatment of primary liver cancer based on the theory of “Wood governing harmony”[J].,2025,46(10):1386-1390.[doi:DOI:10.3969/j.issn.1000-7369.2025.10.017]
点击复制

基于“木曰敷和”理论探讨原发性肝癌的论治
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年10期
页码:
1386-1390
栏目:
学术探讨
出版日期:
2025-10-05

文章信息/Info

Title:
Exploration of the treatment of primary liver cancer based on the theory of “Wood governing harmony”
作者:
谢慰; 刘慧婷; 刘彬彬; 温婉婷婷; 周意; 王若宇; 邓桂明; 伍玉南
（湖南中医药大学第一附属医院，湖南 长沙 410007）
Author(s):
XIE Wei; LIU Huiting; LIU Binbin; WEN Wantingting; ZHOU Yi; WANG Ruoyu; DENG Guiming; WU Yunan
(The First Affiliated Hospital of Hunan University of Chinese Medicine,Changsha 410007,China)
关键词:
原发性肝癌; 黄帝内经; 病因; 病机; 辨证施治
Keywords:
Primary liver cancer; Internal classic of the Yellow Emperor; Etiology; Pathogenesis; Syndrome differentiation and treatment
分类号:
R 735.7
DOI:
DOI:10.3969/j.issn.1000-7369.2025.10.017
文献标志码:
A
摘要:
原发性肝癌是常见的恶性肿瘤，其起病隐匿、发病机制复杂，具有发病率高、预后差、侵袭性强等特点。在这一背景下，中医以其独特的理论体系为原发性肝癌的治疗提供新的视角。“木曰敷和”这一理论出自中医典籍《素问·五常政大论》，与中医理论中原发性肝癌的发生与论治密切相关。本文基于“木曰敷和”理论对原发性肝癌的病因病机以及治疗进行了深入探讨，为中医治疗原发性肝癌提供新思路，以期达到精准施治、提高临床疗效的目的。结果表明，肝气失于敷和是导致肝癌发生的重要病因病机，在原发性肝癌的治疗上应该结合具体临床情况辨证论治，注重扶正祛邪，予以降气或行气之法。
Abstract:
Primary liver cancer (PLC) is a common malignant tumor characterized by insidious onset,complex pathogenesis,high incidence,poor prognosis,and strong invasiveness.Against this backdrop,Traditional chinese medicine (TCM) offers novel perspectives for PLC treatment through its unique theoretical framework.The theory of “Wood governing harmony”,derived from the Suwen:the great treatise on the five constant policies,is closely related to the pathogenesis and therapeutic principles of PLC in TCM theory.This study delves into the etiology,pathogenesis,and treatment of PLC based on the “Wood Governing Harmony” theory,aiming to provide new insights for TCM-based PLC management,with the goal of achieving precise treatment and enhancing clinical efficacy.The results indicate that the failure of liver qi to govern harmony serves as a critical etiological and pathological mechanism in PLC development.In clinical practice,treatment should emphasize syndrome differentiation,integrate reinforcing healthy qi and eliminating pathogenic factors,and employ methods to regulate qi flow through descending or activating strategies.

参考文献/References:

[1]中华人民共和国国家卫生健康委员会,原发性肝癌诊疗指南（2024年版）[J].肿瘤综合治疗电子杂志,2024,10(3):17-68.
[2]王裕新,潘凯枫,李文庆.2022全球癌症统计报告解读[J].肿瘤综合治疗电子杂志,2024,10(3):1-16.
[3]ZOU H,LI M,LEI Q,et al.Economic burden and quality of life of hepatocellular carcinoma in greater China:A systematic review[J].Front Public Health,2022,10:801981.
[4]中国抗癌协会肝癌专业委员会.中国肿瘤整合诊治指南(CACA)-肝癌部分[J].肿瘤综合治疗电子杂志,2022,8(3):31-63.
[5]秦李伟,郭亚荣.肝癌肝移植术后复发影响因素及预测模型的研究进展[J].中华实用诊断与治疗杂志,2025,39(3):283-288.
[6]薛慧敏,陈涛,朱校均.肝癌根治性切除术后患者复发情况及其危险因素分析[J].实用临床医药杂志,2022,26(18):35-38.
[7]邱慧兵,易铁男.FOLFOX7新辅助化疗方案联合肝移植术治疗进展期肝癌的疗效观察[J].河北医药,2017,39(7):1020-1022.
[8]QIN S,CHAN S L,GU S,et al.Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma(CARES-310):A randomised,open-label,international phase 3 study[J].Lancet,2023,402(10408):1133-1146.
[9]LIN J,GUO H,QIN H,et al.Integration of meta-analysis and network pharmacology analysis to investigate the pharmacological mechanisms of traditional Chinese medicine in the treatment of hepatocellular carcinoma[J].Front Pharmacol,2024,15:1374988.
[10]濮忠建,杨军,杨帆,等.基于长链非编码RNA HOX转录反义RNA探讨次乌头原碱对人肝癌SK-Hep-1细胞自噬的影响实验研究[J].陕西医学杂志,2024,53(6):754-758,763.
[11]郭桓博,马瑞雪,朱正望,等.中药基于铁死亡机制防治肝癌研究进展[J].陕西中医,2024,45(2):282-285.
[12]李欣,潘宇飞,万旭英.三氧化二砷在肿瘤治疗中临床应用及相关分子机制研究进展[J].陕西医学杂志,2024,53(5):703-706.
[13]GUO J,ZHAO J,XU Q,et al.Resistance of lenvatinib in hepatocellular carcinoma[J].Curr Cancer Drug Targets,2022,22(11):865-878.
[14]周灏,刘丽丽,施美，等.徐经世国医大师扶正祛邪治疗肝癌经验总结[J].中西医结合肝病杂志,2022,32(2):106-109.
[15]盛丹丹,李振前,陈着，等.吴福宁教授从血瘀论治原发性肝癌临床经验[J].河北中医,2023,45(10):1597-1600.
[16]徐巧笑,胡振斌,莫莎莎,等.从“虚、毒、瘀”浅谈原发性肝癌病机和治疗[J].陕西中医,2023,44(10):1431-1434.
[17]曹莉明,张勇学,梁志会,等.三种不同方法联合TACE治疗原发性肝癌合并食管胃底静脉曲张破裂出血的临床效果[J].医学影像学杂志,2023,33(10):1814-1820.
[18]黄鑫,堵妍,张媛媛.AFP、AFU、CEA、PIVKA-Ⅱ及凝血因子检测在乙型肝炎相关肝癌中的诊断价值[J].哈尔滨医科大学学报,2024,58(6):623-627.
[19]杨丽,张荣臻,吴智鹏,等.柴芍六君子汤在原发性肝癌中的应用进展[J].中医研究,2024,37(8):93-96.
[20]程丑夫.气证论[M].长沙：湖南科学技术出版社,2021:109,177.
[21]李卓娴,徐丽静,夏猛.逍遥散类方治疗肝癌的研究进展[J].环球中医药,2022,15(8):1491-1496.
[22]BOCHIMOTO H,ISHIHARA Y,ZIN N K M,et al.Ultrastructural changes in porcine liver sinusoidal endothelial cells of machine perfused liver donated after cardiac death[J].World J Gastroenterol,2022,28(19):2100-2111.
[23]赵心含,胡霖霖.交泰丸穴位贴敷对心肾不交失眠模型大鼠HPA轴相关激素的影响[J].浙江中西医结合杂志,2024,34(2):129-134.
[24]叶林峰,胡琼力,陈伯勇.补益肝肾汤治疗帕金森病患者自主神经功能障碍疗效观察[J].中医临床研究,2022,14(11):70-72.
[25]EMIN M T,LEE M J,BHATTACHARYA J,et al.Mitochondria of lung venular capillaries mediate lung-liver cross talk in pneumonia[J].Am J Physiol Lung Cell Mol Physio,2023，325(3):277-287.
[26]杨阳,刘洋,刘纪宁,等.血清转氨酶联合Child-Pugh和ALBI评分预测心肺复苏自主循环恢复后缺氧性肝炎患者死亡的价值[J].中国病案,2023,24(1):92-95.
[27]赵娜,隋国媛,柳越冬,等.从脾虚失运论线粒体功能障碍与肝癌[J].辽宁中医杂志,2025,52(1):41-44.
[28]刘琳,周晓玲,吴腾,等.基于“补肾生肝”法探讨济生肾气汤调控骨髓间充质干细胞治疗肝硬化的理论基础[J].中西医结合肝病杂志,2024,34(7):638-641.
[29]DING C,ZHENG Y,LI D,et al.Up-regulation of miR-1925 by bone marrow mesenchymal stem cell(BMSC) inhibits the growth of liver cancer by promoting the anti-tumor activity of natural killer(NK) cells[J].J Biomater Tissue Eng,2022,12(3):630-633.
[30]董锐,张梅,洪泽宣,等.熊胆粉对DEN+PBO诱发大鼠肝癌早期阶段的影响研究[J].中国实验动物学报,2023,31(9):1148-1155.

相似文献/References:

[1]王洪弘,张其成.《黄帝内经》术数理论背景初探*[J].陕西中医,2019,(7):924.
　WANG Honghong,ZHANG Qicheng..Discuss the historical background of number correlation theory in the Huangdi’s Canon on medicine[J].,2019,(10):924.
[2]乔喜婷,王 昊△,杨 林,等.复元活血汤合化积丸联合肝动脉栓塞化疗术治疗原发性肝癌临床研究*[J].陕西中医,2019,(8):998.
　QIAO Xiting,WANG Hao,YANG Lin,et al.Fuyuan Huoxue decoction plus Huaji pills and hepatic artery embolization in the treatment of primary liver cancer[J].,2019,(10):998.
[3]王洪弘,张其成△.从天文实践角度看《黄帝内经》之数*[J].陕西中医,2019,(12):1752.
[4]牛静虎,杨 龙△,宋媛媛.从中土阳明论述强直性脊柱炎*[J].陕西中医,2020,(4):518.
[5]胡欣欣.基于《内经》理论探讨“女子不月”的病机及治法*[J].陕西中医,2020,(7):945.[doi:DOI:10.3969/j.issn.10007369.2020.07.032]
[6]徐 杨,张启明△,王义国,等.“治未病”思想在亚健康防治中的应用*[J].陕西中医,2020,(9):1279.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.029]
[7]曾薇薇,陆齐天,杨冰祎,等.基于“有故无殒,亦无殒也”探讨活血化瘀药物在妊娠病中的运用*[J].陕西中医,2020,(9):1289.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.032]
[8]李 丹,赵 飞,王树庚.疏肝健脾散结汤联合肝动脉插管化疗栓塞术治疗原发性肝癌疗效研究[J].陕西中医,2021,(6):728.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.012]
　LI Dan,ZHAO Fei,WANG Shugeng.Effect of Shugan Jianpi Sanjie decoction combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer[J].,2021,(10):728.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.012]
[9]赵培西,许建秦,袁 彬,等.扶正抗癌方治疗肝癌肝郁脾虚瘀毒证临床研究[J].陕西中医,2022,(12):1746.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.022]
[10]周 林,肖 康,夏建辉.八珍汤加减辅助治疗原发性肝癌疗效及对患者外周血Th17/Treg平衡和不良反应的影响[J].陕西中医,2023,(9):1216.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.013]
　ZHOU Lin,XIAO Kang,XIA Jianhui.Effect of modified Bazhen decoction adjuvant therapy on peripheral blood Th17/Treg balance and adverse reactions in patients with primary liver cancer[J].,2023,(10):1216.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.013]

备注/Memo

备注/Memo:
湖南省科学技术厅课题（2024JJ5314）；湖南省中医药科研基金资助项目（C2023008）；湖南省教育厅重点项目（23A0305）
更新日期/Last Update: 2025-10-10